| Name | Title | Contact Details |
|---|
California Imaging Svc is a Fairfield, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UCM Digital Health (UCM) delivers an end-to-end digital first healthcare solution that combines a digital front door platform with a 24/7 emergency medicine treat, triage and navigation telehealth service – designed to lower costs, improve outcomes and provide a better patient experience. UCM Digital Health brings together clinical expertise, advanced technology and compassionate care to offer powerful advantages for insurers, brokers, employers, patients and providers. UCM Digital Health partners with insurers, employers, patients, providers, technology solutions companies – covering every corner of the healthcare ecosystem to deliver a complete, trusted, technology-based and data-driven healthcare solution. UCM Digital Health`s unique combination of digital front door platform plus emergency medicine triage and navigation expertise allows all care to begin digitally in one place. Located in Troy, New York, UCM Digital Health was founded in 2015 by emergency clinicians Keith Algozzine, PA-C and Michael Bibighaus, M.D., in an effort to combine healthcare and technology who continue to run the operations of the company.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Complete Healthcare Communications Inc is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Verathon (formerly Diagnostic Ultrasound Corporation) designs, manufactures and distributes reliable, state-of-the-art medical devices and services that offer a meaningful improvement in patient care to the health care community.